340 related articles for article (PubMed ID: 27159579)
1. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.
Sdelci S; Lardeau CH; Tallant C; Klepsch F; Klaiber B; Bennett J; Rathert P; Schuster M; Penz T; Fedorov O; Superti-Furga G; Bock C; Zuber J; Huber KV; Knapp S; Müller S; Kubicek S
Nat Chem Biol; 2016 Jul; 12(7):504-10. PubMed ID: 27159579
[TBL] [Abstract][Full Text] [Related]
2. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.
Crawford TD; Tsui V; Flynn EM; Wang S; Taylor AM; Côté A; Audia JE; Beresini MH; Burdick DJ; Cummings R; Dakin LA; Duplessis M; Good AC; Hewitt MC; Huang HR; Jayaram H; Kiefer JR; Jiang Y; Murray J; Nasveschuk CG; Pardo E; Poy F; Romero FA; Tang Y; Wang J; Xu Z; Zawadzke LE; Zhu X; Albrecht BK; Magnuson SR; Bellon S; Cochran AG
J Med Chem; 2016 Jun; 59(11):5391-402. PubMed ID: 27219867
[TBL] [Abstract][Full Text] [Related]
3. Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains.
Bouché L; Christ CD; Siegel S; Fernández-Montalván AE; Holton SJ; Fedorov O; Ter Laak A; Sugawara T; Stöckigt D; Tallant C; Bennett J; Monteiro O; Díaz-Sáez L; Siejka P; Meier J; Pütter V; Weiske J; Müller S; Huber KVM; Hartung IV; Haendler B
J Med Chem; 2017 May; 60(9):4002-4022. PubMed ID: 28402630
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
Gold S; Shilatifard A
Curr Opin Genet Dev; 2024 Jun; 86():102181. PubMed ID: 38564841
[TBL] [Abstract][Full Text] [Related]
5. Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1.
Wu Q; Chen DQ; Sun L; Huan XJ; Bao XB; Tian CQ; Hu J; Lv KK; Wang YQ; Xiong B; Miao ZH
Biochem Pharmacol; 2021 Mar; 185():114435. PubMed ID: 33539817
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective bivalent inhibitors of BET bromodomains.
Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
[TBL] [Abstract][Full Text] [Related]
7. TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S
Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040
[TBL] [Abstract][Full Text] [Related]
8. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG
Structure; 2015 Oct; 23(10):1801-1814. PubMed ID: 26365797
[TBL] [Abstract][Full Text] [Related]
9. TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter.
Hilton TL; Li Y; Dunphy EL; Wang EH
Mol Cell Biol; 2005 May; 25(10):4321-32. PubMed ID: 15870300
[TBL] [Abstract][Full Text] [Related]
10. The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains.
Weissman JD; Singh AK; Devaiah BN; Schuck P; LaRue RC; Singer DS
J Biol Chem; 2021 Nov; 297(5):101326. PubMed ID: 34688663
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of a TAF1-TAF7 complex in human transcription factor IID reveals a promoter binding module.
Wang H; Curran EC; Hinds TR; Wang EH; Zheng N
Cell Res; 2014 Dec; 24(12):1433-44. PubMed ID: 25412659
[TBL] [Abstract][Full Text] [Related]
12. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
13. Zinc knuckle of TAF1 is a DNA binding module critical for TFIID promoter occupancy.
Curran EC; Wang H; Hinds TR; Zheng N; Wang EH
Sci Rep; 2018 Mar; 8(1):4630. PubMed ID: 29545534
[TBL] [Abstract][Full Text] [Related]
14. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
[TBL] [Abstract][Full Text] [Related]
16. An Overview on Small Molecule Inhibitors of BRD4.
Huang W; Zheng X; Yang Y; Wang X; Shen Z
Mini Rev Med Chem; 2016; 16(17):1403-1414. PubMed ID: 27290915
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain.
Karim RM; Yang L; Chen L; Bikowitz MJ; Lu J; Grassie D; Shultz ZP; Lopchuk JM; Chen J; Schönbrunn E
J Med Chem; 2022 Mar; 65(5):4182-4200. PubMed ID: 35191694
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide relationships between TAF1 and histone acetyltransferases in Saccharomyces cerevisiae.
Durant M; Pugh BF
Mol Cell Biol; 2006 Apr; 26(7):2791-802. PubMed ID: 16537921
[TBL] [Abstract][Full Text] [Related]
19. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin.
Devaiah BN; Case-Borden C; Gegonne A; Hsu CH; Chen Q; Meerzaman D; Dey A; Ozato K; Singer DS
Nat Struct Mol Biol; 2016 Jun; 23(6):540-8. PubMed ID: 27159561
[TBL] [Abstract][Full Text] [Related]
20. Multiple direct interactions of TBP with the MYC oncoprotein.
Wei Y; Resetca D; Li Z; Johansson-Åkhe I; Ahlner A; Helander S; Wallenhammar A; Morad V; Raught B; Wallner B; Kokubo T; Tong Y; Penn LZ; Sunnerhagen M
Nat Struct Mol Biol; 2019 Nov; 26(11):1035-1043. PubMed ID: 31686052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
